Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Gross Margin: 2021-2025

Historic Gross Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 100.00%.

  • Allogene Therapeutics' Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of 100.00% for FY2024, which is negligibly% changed negligibly from last year.
  • As of Q3 2025, Allogene Therapeutics' Gross Margin stood at 100.00%, which was down 0.00% from 100.00% recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Gross Margin high stood at 100.00% for Q1 2021, and its period low was 100.00% during Q1 2021.
  • For the 3-year period, Allogene Therapeutics' Gross Margin averaged around 100.00%, with its median value being 100.00% (2025).